When and how should digoxin be used in patients with heart failure with reduced ejection fraction (HFrEF) and hypertrophic obstructive cardiomyopathy (HOCM), including appropriate dosing, monitoring, and contraindications?

Digoxin in HFrEF and HOCM

HFrEF: Use Digoxin Selectively for Symptom Control, Not Mortality

In patients with HFrEF, digoxin might be considered only after optimizing guideline-directed medical therapy (GDMT) to reduce heart failure hospitalizations, but it provides no mortality benefit and should be dosed at 0.125-0.25 mg daily with lower doses (0.125 mg or every other day) for patients >70 years, impaired renal function, or low lean body mass. 1

When to Use Digoxin in HFrEF

The 2022 AHA/ACC/HFSA guidelines give digoxin a Class 2b recommendation (Level B-R evidence), meaning it "might be considered" but is not strongly recommended 1. This reflects the limited evidence base:

• Only one large RCT exists (the DIG trial), which predated modern GDMT and showed no mortality benefit but modest reduction in the combined endpoint of death and hospitalization 1
• The trial found no significant effect on quality of life 1
• Retrospective analyses have consistently shown either no mortality benefit or increased mortality with digoxin, particularly at higher doses 1

Appropriate candidates:

• Patients with persistent NYHA class II-IV symptoms despite optimal doses of ACE inhibitors/ARNIs, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors
• Patients unable to tolerate GDMT components
• Patients with concurrent atrial fibrillation requiring rate control

Dosing Strategy for HFrEF

Standard dosing 1, 2:

• Initial dose: 0.125-0.25 mg once daily for most patients
• Reduced dose: 0.125 mg daily or every other day for:
  • Age >70 years
  • Impaired renal function (CrCl <60 mL/min)
  • Low lean body mass
  • Marked renal impairment: 0.0625 mg daily

Higher doses (0.375-0.5 mg daily) are rarely needed and potentially harmful 1, 2

Monitoring Requirements

Serum digoxin levels 2:

• Target therapeutic range: 0.5-0.9 ng/mL (lower than historically recommended)
• Sample timing: Just before next dose, or at least 6-8 hours post-dose
• Routine monitoring is unnecessary unless toxicity suspected
• Toxicity commonly occurs at levels >2 ng/mL but can occur at lower levels with hypokalemia, hypomagnesemia, or hypothyroidism

Clinical monitoring:

• Renal function (affects clearance)
• Electrolytes (hypokalemia and hypomagnesemia increase toxicity risk)
• Heart rate and rhythm
• Signs of toxicity: nausea, visual disturbances, arrhythmias

Critical Pitfalls

Drug interactions that increase digoxin levels 2:

• Amiodarone (reduce digoxin dose by 50%)
• Verapamil
• Quinidine
• Spironolactone
• Flecainide

Renal dosing is essential: Digoxin is primarily renally cleared, and failure to adjust for renal function is a common cause of toxicity 2, 3

---

HOCM: Avoid Digoxin in Obstructive Disease

In patients with hypertrophic obstructive cardiomyopathy (HOCM), digoxin should be avoided when left ventricular outflow tract obstruction (LVOTO) is present due to its positive inotropic effect that can worsen the gradient; however, in the absence of obstruction, digoxin may be considered for rate control in atrial fibrillation, though data on efficacy are lacking. 4

The Theoretical Concern

The 2024 AHA/ACC guideline explicitly states: "A theoretical concern exists that digoxin could exacerbate LVOTO attributable to a positive inotropic effect" 4. This is based on the mechanism that increased contractility worsens dynamic obstruction in HOCM.

When Digoxin Might Be Acceptable in HOCM

Only in non-obstructive cases 4:

• Patients with HCM but no resting or provocable gradient
• Primary indication: rate control for atrial fibrillation
• Caveat: Data on efficacy in this population are lacking 4

Preferred Rate Control Agents in HOCM with AF

First-line options 4:

• Non-dihydropyridine calcium channel blockers (verapamil, diltiazem)
• Beta-blockers
• Combination of both

Special considerations:

• Avoid verapamil in patients with hypotension, dyspnea at rest, or very high resting gradients (>100 mm Hg) 4
• Atrioventricular node ablation with pacemaker is a last resort for refractory cases 4

Anticoagulation Takes Priority

In HOCM patients with atrial fibrillation, rhythm control is generally preferred over rate control due to poor tolerance of AF in this population 4. Anticoagulation decisions follow standard CHA₂DS₂-VASc scoring, and device-detected AF >24 hours or shorter episodes with CHA₂DS₂-VASc ≥2 warrant anticoagulation 4.

---

Key Algorithmic Approach

For HFrEF:

1. Optimize GDMT first (ACEi/ARNi, beta-blocker, MRA, SGLT2i)
2. If persistent symptoms → consider digoxin 0.125-0.25 mg daily
3. Adjust for age >70, renal function, body mass
4. Monitor for drug interactions (especially amiodarone)
5. Check levels only if toxicity suspected

For HOCM:

1. Assess for LVOTO (echo with provocation)
2. If gradient present → avoid digoxin
3. If no gradient + AF → digoxin is an option but not preferred
4. Prefer beta-blockers or calcium channel blockers for rate control